Actos (Pioglitazone) Cost in New Mexico 2026

What Pioglitazone Actually Is, and Why Dose Matters for Cost

Pioglitazone is a thiazolidinedione (TZD) insulin sensitizer that activates peroxisome proliferator-activated receptor gamma (PPAR-gamma). The FDA approved it for type 2 diabetes mellitus as an adjunct to diet and exercise in 1999. Actos prescribing information is archived at the FDA.

How PPAR-gamma Activation Affects Glucose

By binding PPAR-gamma in adipose tissue, pioglitazone redistributes fat away from visceral depots and toward subcutaneous tissue. This redistribution improves insulin sensitivity in muscle and liver independently of weight change. A 2005 meta-analysis published in Diabetes Care found that pioglitazone reduced HbA1c by a mean of 0.9 to 1.0 percentage points versus placebo across 22 randomized trials. See the PubMed record.

Doses Available, and How They Affect Price

Pioglitazone comes in 15 mg, 30 mg, and 45 mg tablets. Generic tablets at all three strengths typically cost within a dollar or two of each other per month at New Mexico pharmacies. Splitting a 30 mg tablet is not recommended because tablet coating may affect absorption. Always confirm the specific strength on your prescription before comparing pharmacy prices.

Off-Label NASH Use, the PIVENS Trial

The PIVENS trial (N=247, published in NEJM 2010) tested pioglitazone 30 mg daily versus vitamin E versus placebo in adults with nonalcoholic steatohepatitis without diabetes. Pioglitazone met the primary histologic endpoint in 34% of participants versus 19% in the placebo arm (P<0.04). Full PIVENS data are on PubMed. The American Association for the Study of Liver Diseases (AASLD) 2023 guidance states: "Pioglitazone may be used to treat biopsy-proven NASH in patients with or without type 2 diabetes." AASLD practice guidance is indexed at PubMed.

Generic vs. Brand Actos: Real 2026 Prices in New Mexico

Generic pioglitazone costs about $15 per month at New Mexico retail pharmacies in 2026. Brand Actos (Takeda) lists near $60 per month. That four-fold gap makes the generic the obvious starting point for most patients.

Why the Gap Exists

Takeda's original Actos patents expired in 2012. Multiple manufacturers now supply generic pioglitazone tablets. Increased competition has driven the average wholesale price (AWP) of 30 mg generic tablets below $0.60 per tablet at most wholesalers. The FDA maintains a list of approved generic pioglitazone products on its Orange Book. FDA Orange Book entry for pioglitazone.

Cash-Pay Pharmacy Prices Across New Mexico

Prices vary by pharmacy chain and by city. GoodRx and similar discount platforms negotiate below the standard cash price at many Albuquerque, Santa Fe, Las Cruces, and Rio Rancho pharmacies. Prices as low as $9, $12 per month have been documented at Walmart and Costco pharmacies in New Mexico using discount coupons. GoodRx pricing methodology is described in their published analysis.

Pharmacies in smaller New Mexico communities, Gallup, Farmington, Roswell, may not be enrolled in all discount networks. Calling ahead to confirm coupon acceptance saves time.

Manufacturer Savings Cards

Takeda offers a savings card for brand Actos that may reduce co-pays for commercially insured patients. Eligible patients may pay as little as $25 per fill at participating pharmacies. The card does not apply to Medicaid, Medicare Part D, or other federal programs. Patients should check current eligibility at Takeda's patient support portal because terms change annually.

New Mexico Medicaid (Centennial Care) Coverage for Pioglitazone

New Mexico Medicaid does not currently cover pioglitazone for type 2 diabetes or for off-label NASH treatment under its Centennial Care program. This is a significant coverage gap because New Mexico has one of the highest rates of type 2 diabetes in the country.

Why Medicaid Excludes It

New Mexico's Preferred Drug List (PDL) managed by the Human Services Department typically favors metformin, sulfonylureas, and certain SGLT2 inhibitors or GLP-1 receptor agonists that have secured supplemental rebate agreements. Pioglitazone, despite its low cost, does not always appear on state PDLs because manufacturers of branded TZDs historically did not compete aggressively for Medicaid formulary placement. CMS guidance on state PDL construction is available on Medicaid.gov.

Prior Authorization as an Alternative Path

A prescribing clinician can submit a prior authorization (PA) request documenting medical necessity, particularly for patients who have failed metformin and sulfonylureas. PA approval is not guaranteed but may succeed when chart documentation shows HbA1c above 7.5% despite two or more prior agents and a clinical reason to avoid GLP-1 agonists (e.g., gastroparesis, cost, intolerance). ADA Standards of Care 2024 address stepwise intensification.

Medicare Part D in New Mexico

Medicare Part D plans in New Mexico vary by formulary. Most Part D plans place generic pioglitazone on Tier 1 or Tier 2, where co-pays range from $0 to $10 per month. Patients in the Low-Income Subsidy (LIS / Extra Help) program typically pay $0 to $4. Checking the Medicare Plan Finder at cms.gov before each open enrollment period is advisable because tier placement shifts annually.

Commercial Insurance Coverage in New Mexico

Most commercial plans available through New Mexico's BeWellNM exchange cover generic pioglitazone on Tier 1 (preferred generic), with co-pays typically between $0 and $15 per month after deductible. Brand Actos usually sits on Tier 3 or Tier 4, with co-pays of $50, $150 per fill.

Step-Therapy Requirements

Several New Mexico plan administrators require step therapy: a patient must try and fail metformin (and sometimes a sulfonylurea) before pioglitazone is approved. The ADA 2024 Standards of Medical Care in Diabetes note that metformin "remains first-line for most patients with type 2 diabetes" but that TZDs are appropriate second- or third-line agents, especially when cost and tolerability are concerns. ADA Standards 2024, PubMed.

Employer Plans (ERISA Plans)

Large employer plans in New Mexico (state government, University of New Mexico Health System, Intel, Sandia National Laboratories) typically mirror commercial formularies. ERISA plans are regulated federally, not by New Mexico's Insurance Division, so state-mandated step-therapy exceptions do not automatically apply. Patients appealing a coverage denial should request the plan's Evidence of Coverage document and cite the treating physician's medical necessity letter.

Getting a Step-Therapy Exception

The New Mexico Patient Protection Act (NMSA 1978, Section 59A-57-1 et seq.) requires state-regulated insurers to have an exceptions process. To win an exception:

1. The prescriber documents failure of or contraindication to required step agents.
2. A board-certified endocrinologist or primary care physician submits a clinical rationale letter.
3. The insurer must respond within 72 hours for urgent requests.

The New Mexico Office of Superintendent of Insurance publishes consumer guidance. ERISA plans follow federal timelines under DOL regulations. DOL claims procedure rule is referenced on HHS's ACA resources page.

Compounded Pioglitazone in New Mexico: Legality and Availability

Compounded pioglitazone prepared by a state-licensed 503A pharmacy is legal in New Mexico. A 503A pharmacy may compound pioglitazone for an individual patient when a licensed prescriber issues a valid, patient-specific prescription.

What 503A Means

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a compounding pharmacy may prepare customized drug formulations for specific patients without FDA pre-market approval, provided the compounded preparation is not a copy of a commercially available drug and meets USP standards. FDA's 503A guidance document is available at fda.gov.

The "Not a Commercially Available Drug" Nuance

Standard pioglitazone tablets are commercially available. A compounding pharmacy must therefore justify the preparation on clinical grounds, for example by compounding a suspension for a patient with dysphagia who cannot swallow tablets, or a formulation at a non-commercially available strength for a pediatric patient. Compounding a standard 30 mg tablet simply to avoid cost likely does not meet the 503A threshold. Prescribers and patients should discuss this with a licensed compounding pharmacist before assuming coverage.

Cost of Compounded Pioglitazone

Where a clinical justification is accepted and the compounded formulation is covered under a telehealth program's dispensing arrangement, patients have reported $0 out-of-pocket cost. Outside those arrangements, compounded pioglitazone typically costs $20, $40 per month at New Mexico 503A pharmacies, still competitive with or below brand Actos. USP compounding standards referenced in FDA guidance.

HealthRX 503A Eligibility Framework for Pioglitazone in New Mexico

| Patient Situation | 503A Compounding Appropriate? | Estimated Monthly Cost | |---|---|---| | Standard T2D, can swallow tablets | Generally no (commercial tabs available) | N/A | | Dysphagia requiring liquid suspension | Yes, with prescriber documentation | $20, $40 | | Pediatric off-label dosing (non-standard strength) | Yes, with prescriber documentation | $20, $40 | | NASH patient in telehealth program | Depends on program structure; confirm with pharmacist | $0, $40 |

Telehealth Prescribing of Pioglitazone in New Mexico

Telehealth prescribing of pioglitazone is fully legal in New Mexico. A licensed New Mexico clinician may evaluate a patient via synchronous audio-video telehealth and issue a prescription for pioglitazone without a prior in-person visit, provided the clinician completes an appropriate clinical assessment. New Mexico's telehealth law (HB 142, 2021) is summarized by the NM Medical Board.

What the Telehealth Visit Should Include

A complete telehealth evaluation for pioglitazone should include review of recent HbA1c (ideally within 3 months), a medication history, and screening for contraindications: active bladder cancer history, New York Heart Association Class III, IV heart failure, or active hepatic disease. The FDA label specifies that pioglitazone is contraindicated in patients with established NYHA Class III or IV heart failure. FDA label contraindications are documented on accessdata.fda.gov.

Monitoring Requirements After Prescribing

The American Diabetes Association recommends monitoring liver enzymes at baseline if clinical liver disease is suspected. ADA Standards 2024. Weight and edema should be assessed at 8 to 12 weeks after initiation because fluid retention occurs in approximately 4 to 8% of patients receiving pioglitazone, based on the PROactive trial (N=5,238). PROactive cardiovascular outcomes data, PubMed.

The PROactive trial also demonstrated a 16% relative risk reduction in the secondary composite endpoint (all-cause mortality, nonfatal MI, stroke) with pioglitazone 45 mg versus placebo (HR 0.84, 95% CI 0.72 to 0.98, P<0.027) in patients with type 2 diabetes and established cardiovascular disease. PROactive, PubMed.

Discount Programs and Patient Assistance in New Mexico

Several cost-reduction pathways exist for New Mexico patients who pay cash or have inadequate coverage.

GoodRx and Competing Coupon Platforms

GoodRx, RxSaver, and NeedyMeds all negotiate discounted rates at retail pharmacies. At major New Mexico chains (Walgreens, CVS, Walmart, Smith's/Kroger), generic pioglitazone 30 mg has been priced as low as $9 per 30-day supply with a coupon. NeedyMeds publishes a drug discount database at needymeds.org.

Takeda Patient Assistance Program

Takeda operates the Takeda Patient Assistance Program (TAP) for brand Actos. Uninsured or underinsured patients with household incomes at or below 400% of the federal poverty level may qualify for free or reduced-cost medication. Applications are submitted via Takeda's support line. Because generic pioglitazone costs $9, $15 per month, most patients will find the generic more accessible than navigating brand assistance, but the TAP option exists for patients who require Actos specifically.

New Mexico's Low-Income Pharmaceutical Program

The New Mexico Human Services Department administers supplemental assistance programs for low-income residents. Eligibility for these programs may overlap with Medicaid Centennial Care. Patients not enrolled in Medicaid but below 138% of the federal poverty level should contact the NM HSD at 1-800-283-4465 to determine eligibility for pharmacy assistance. HSD benefit overview at hsd.state.nm.us.

340B Program Pharmacies in New Mexico

Federally qualified health centers (FQHCs) and rural health clinics in New Mexico participate in the 340B Drug Pricing Program, which allows them to purchase drugs at significantly reduced prices and pass savings to patients. New Mexico FQHCs include First Choice Community Healthcare (Albuquerque), La Familia Medical Center (Santa Fe), and Hidalgo Medical Services (Lordsburg). Patients seen at these clinics may access pioglitazone at 340B pricing, which can be below $5 per month. HRSA maintains the 340B database at hrsa.gov.

Clinical Efficacy Data New Mexico Prescribers Rely On

Pioglitazone's evidence base is substantial. Knowing the key trials helps patients and prescribers make informed decisions.

UKPDS 34 Context for TZD Class

The UK Prospective Diabetes Study (UKPDS 34, N=1,704) established that intensive glycemic control with metformin reduced diabetes-related endpoints by 32% in overweight patients, setting the benchmark against which TZDs are compared. UKPDS 34, PubMed. Pioglitazone did not feature in UKPDS but its HbA1c-lowering effect (0.9 to 1.0 percentage points) is comparable to metformin's effect in that trial.

PROactive: Cardiovascular Outcomes

The PROactive trial enrolled 5,238 patients with type 2 diabetes and macrovascular disease. Pioglitazone 45 mg daily over 34.5 months reduced the secondary composite cardiovascular endpoint (HR 0.84, P<0.027) while increasing fluid retention and heart failure hospitalization by approximately 2 percentage points. Patients with NYHA Class I, II heart failure were not excluded but outcomes were monitored closely. PROactive, PubMed.

PIVENS: NASH Histology

PIVENS (N=247) demonstrated that pioglitazone 30 mg daily for 96 weeks improved NASH histology in 34% of participants versus 19% placebo (P<0.04), with significant reductions in hepatocyte ballooning and lobular inflammation scores. PIVENS, PubMed. Weight gain of approximately 4.7 kg occurred in the pioglitazone arm, a tradeoff to discuss with patients.

Bladder Cancer Signal: What the FDA Label Says

The FDA added a warning in 2011 about a possible association between pioglitazone use exceeding 12 months and bladder cancer risk. A 10-year epidemiologic study (N=193,099, Kaiser Permanente) found a hazard ratio of 1.4 (95% CI 1.03 to 1.97) for bladder cancer in patients with over 24 months of pioglitazone use. Kaiser Permanente bladder cancer study, PubMed. The absolute risk remains low (approximately 2 additional cases per 10,000 patient-years), but the FDA label states pioglitazone should not be used in patients with active bladder cancer and should be used with caution in patients with a prior history. FDA Drug Safety Communication on pioglitazone and bladder cancer.

How to Get the Lowest Pioglitazone Price in New Mexico: A Step-by-Step Path

Most New Mexico patients can pay $9, $15 per month for generic pioglitazone without any assistance program. Follow these steps in order.

Step 1: Confirm Generic Is Prescribed

Ask your prescriber to write "pioglitazone" (generic) rather than "Actos." Dispense-as-written (DAW-1) codes on brand prescriptions block pharmacists from substituting generics even when available.

Step 2: Run a Coupon Comparison at the Point of Dispensing

Before paying, ask the pharmacist to run GoodRx, RxSaver, or ScriptSave WellRx. The lowest price at Walmart Pharmacy in Albuquerque as of late 2024 was $9.34 for 30 tablets of pioglitazone 30 mg. That price is often lower than most insurance co-pays. GoodRx pricing analysis referenced in peer-reviewed literature.

Step 3: Check 340B Clinic Eligibility

If you receive primary care at a federally qualified health center, ask whether the center participates in 340B dispensing. HRSA's 340B database lists all participating entities by ZIP code. HRSA 340B database.

Step 4: Appeal Medicaid or Insurance Denial With PA

If Medicaid denied coverage, a prior authorization citing medical necessity (documented HbA1c, prior drug failures, clinical rationale) has a nonzero success rate. The New Mexico Medical Board requires insurers to respond to standard PA requests within 3 business days. NM Insurance Division consumer guidance.

Step 5: Consider a Telehealth Program With Compounding Pharmacy Partnership

Some telehealth platforms partner directly with 503A compounding pharmacies for patients whose clinical profile justifies a non-standard formulation. Where that arrangement is valid and covered, out-of-pocket cost can drop to $0. Confirm with the platform that the compounding pharmacy is New Mexico-licensed and that the clinical indication meets 503A criteria before enrolling. FDA 503A overview.